There
government
licensed
viral
gene
therapy
products
currently
use
head
neck
cancer
,
utilised
conjunction
established
treatment
modalities
.

The
viruses
target
tumour-associated
genes
,
first
licensed
virus
replacing
p53
gene
function
,
frequently
lost
tumourigenesis
.

Oncolytic
viruses
selectively
destroy
cancer
cells
viral
replication
armed
therapeutic
transgenes
.

